ClinicalTrials.gg
CompletedNCT06483243Updated Jul 3, 2024

Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State.

A Phase 1 interventional study of Test: CKD-383, Reference1: Duvie Tab. 0.5mg, Reference2: Jardiance tablets 25 mg, Reference3: GLUCOPHAGE XR TAB. 1000MG in Type 2 Diabetes Mellitus, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-03.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
19 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 64 studies in Diabetes Mellitus, Type 2 by Chong Kun Dang Pharmaceutical — 3 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Chong Kun Dang Pharmaceutical.

Enrollment
13th of 62
45 · median 30
Started
2024
with 7 others
Phase 1
53 of 64
1 open now
Registered
54th of 64
by date

Among the 64 studies in Diabetes Mellitus, Type 2 by Chong Kun Dang Pharmaceutical, this one is the 13th largest by enrollment of the 62 interventional ones that give a count, is one of 8 that started in 2024, is one of 53 in phase 1, and was the 54th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 64 studies in Diabetes Mellitus, Type 2 by Chong Kun Dang Pharmaceutical are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 19 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Diabetes Mellitus, Type 2 by Chong Kun Dang Pharmaceutical, or all of them as a file.
02

Study summary

This is a Randomized, open-label, single oral dosing, two-sequence, and two-period crossover study to evaluate the pharmacokinetics and safety between the administration of CKD-383 and the co-administration of CKD-501, D745, and D150 for healthy subjects in fed state

Read the detailed description

Participants were randomly assigned in a 1:1 ratio. The patients are prescribed oral administration of the appropriate IP(2 or 4 tablets in single dose: actual medication)

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults aged 19 to 65 years
  • Based on screening, no congenital or chronic disease, who have no athological symptoms or findings(If necessary, EEG, , chest and gastroscopy or gastrointestinal radiation, Examination)
  • within 5 years prior to the start of the trial(Period 1 administration) of any mental medical history
  • Other inclusion criteria, as defined in the protocol

Exclusion criteria

Exclusion Criteria:

  • who has taken drug metabolism enzyme induction and inhibitory drugs, such as barbitale drugs, within 30 days prior to the start of the trial (Period 1 administration)
  • Other exclusive criteria, as defined in the protocol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Group A

    * Phase 1: CKD-501 1 tablet, D745 1 tablet, D150 2 tablets(Reference) * Phase 2: CKD-383 2 tablets(Test)

    Drug: Test: CKD-383, Reference1: Duvie Tab. 0.5mg, Reference2: Jardiance tablets 25 mg, Reference3: GLUCOPHAGE XR TAB. 1000MG

  • Experimental
    Group B

    * Phase 1: CKD-383 2 tablets(Test) * Phase 2: CKD-501 1 tablet, D745 1 tablet, D150 2 tablets(Reference)

    Drug: Test: CKD-383, Reference1: Duvie Tab. 0.5mg, Reference2: Jardiance tablets 25 mg, Reference3: GLUCOPHAGE XR TAB. 1000MG

Interventions

  • DrugTest: CKD-383, Reference1: Duvie Tab. 0.5mg, Reference2: Jardiance tablets 25 mg, Reference3: GLUCOPHAGE XR TAB. 1000MG

    At around 8 a.m., take Test drug or Reference drug 1,2,3(oral) with 200 mL of water at room temperature.

    Also known as: Test: CKD-383, Reference1: CKD-501, Reference2: D745, Reference3: D150

06

What researchers measure

Primary outcomes

  1. AUCt of Lobeglitazone, Empagliflozin, Metformin

    Pharmacokinetic characterization

    Time frame: 0 hour ~ 48 hour after drug administration

  2. Cmax of Lobeglitazone, Empagliflozin, Metformin

    Pharmacokinetic characterization

    Time frame: 0 hour ~ 48 hour after drug administration

Secondary outcomes

  1. AUC∞ of Lobeglitazone, Empagliflozin, Metformin

    Pharmacokinetic characterization

    Time frame: 0 hour ~ 48 hour after drug administration

  2. Tmax of Lobeglitazone, Empagliflozin, Metformin

    Pharmacokinetic characterization

    Time frame: 0 hour ~ 48 hour after drug administration

  3. T1/2 of Lobeglitazone, Empagliflozin, Metformin

    Pharmacokinetic characterization

    Time frame: 0 hour ~ 48 hour after drug administration

  4. CL/F of Lobeglitazone, Empagliflozin, Metformin

    Pharmacokinetic characterization

    Time frame: 0 hour ~ 48 hour after drug administration

  5. Vd/F of Lobeglitazone, Empagliflozin, Metformin

    Pharmacokinetic characterization

    Time frame: 0 hour ~ 48 hour after drug administration

07

Study locations

1 site
  • Chung-Ang University Gwangmyeong Hospital
    Gyeonggi-do, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Apr 2024, 0 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 0 months is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2024
First posted
Jul 3, 2024
StartActual
Apr 4, 2024
Primary completionActual
Apr 29, 2024
CompletionActual
May 17, 2024
Last update
Jul 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06483243
Responsible party
Sponsor
First posted
Jul 3, 2024
Start date
Apr 4, 2024
Primary completion
Apr 29, 2024
Completion
May 17, 2024
Last update
Jul 3, 2024

Study contacts

Yun Hwan Oh, PI
principal investigator · Chung-Ang University Gwangmyeong Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion